Literature DB >> 27766418

The effects of high serum growth hormone and IGF-1 levels on bone mineral density in acromegaly.

S Tuzcu1, Ş A Durmaz2,3, A Carlıoğlu4, Z Demircan5, A Tuzcu6, C Beyaz6, A Tay4.   

Abstract

OBJECTIVE: Growth hormone (GH) and insulin-like growth factor-1 (IGF-1) play a major role in bone homeostasis. In this study, we aimed to assess bone mineral density (BMD) in active acromegaly.
MATERIALS AND METHODS: A total of 29 patients with active acromegaly (age 46.10 ± 13.27 years; body mass index [BMI]: 29.51 ± 4.91 kg/m2) and 42 healthy individuals matched for age and BMI (age: 40.35 ± 11.74 years; BMI: 28.18 ± 7.35 kg/m2) were included in the study. BMD was measured by DXA.
RESULTS: The mean levels of GH and IGF-1 were found to be 12.61 ± 11.34 ng/ml and 676.47 ± 316.19 ng/ml in acromegaly, respectively, while the mean levels of GH and IGF-1 were found to be 0.59 ± 0.81 ng/ml (p = 0.0001) and 178.17 ± 57.11 ng/ml (p = 0.0001) in the control group, respectively. Only total hip t‑score was determined to be significantly lower in acromegaly compared to the control group (p = 0.037). No significant differences were found between the other parameters in DXA and only a positive correlation was found between IGF-1 levels and L1-L4 BMD (r = 0.259, p = 0.029).
CONCLUSIONS: Although GH and IGF-1 levels were increased in acromegalic patients, no significant difference was found in terms of vertebral BMD. Only hip t‑scores were found to be lower in acromegalic patients, but this low hip t‑score did not reach the osteopenic level. The positive correlation between IGF-1 and lumbar vertebral BMD suggested a more prominent effect of IGF-1 on BMD compared to GH.

Entities:  

Keywords:  Acromegaly; Bone mineral density; Insulin like growth factor‑1 (IGF‑1)

Mesh:

Substances:

Year:  2017        PMID: 27766418     DOI: 10.1007/s00393-016-0171-6

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  34 in total

1.  Bone mineral density and turnover in patients with acromegaly in relation to sex, disease activity, and gonadal function.

Authors:  Marek Bolanowski; Jacek Daroszewski; Marek Medraś; Beata Zadrozna-Sliwka
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

Review 2.  The action of GH/IGF-I/IGFBP in osteoblasts and osteoclasts.

Authors:  K Chihara; T Sugimoto
Journal:  Horm Res       Date:  1997

Review 3.  The effect of GH and IGF1 on linear growth and skeletal development and their modulation by SOCS proteins.

Authors:  S F Ahmed; C Farquharson
Journal:  J Endocrinol       Date:  2010-07-14       Impact factor: 4.286

4.  The insulin-like growth factor system: towards clinical applications.

Authors:  Leon A Bach
Journal:  Clin Biochem Rev       Date:  2004-08

Review 5.  The anabolic effects of GH/IGF system on bone.

Authors:  Yuji Kasukawa; Naohisa Miyakoshi; Subburaman Mohan
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

6.  Prevalence of vertebral fractures in men with acromegaly.

Authors:  Gherardo Mazziotti; Antonio Bianchi; Stefania Bonadonna; Vincenzo Cimino; Ilaria Patelli; Alessandra Fusco; Alfredo Pontecorvi; Laura De Marinis; Andrea Giustina
Journal:  J Clin Endocrinol Metab       Date:  2008-09-30       Impact factor: 5.958

7.  Acromegaly has a negative influence on trabecular bone, but not on cortical bone, as assessed by high-resolution peripheral quantitative computed tomography.

Authors:  Miguel Madeira; Leonardo Vieira Neto; Francisco de Paula Paranhos Neto; Inayá Corrêa Barbosa Lima; Laura Maria Carvalho de Mendonça; Mônica Roberto Gadelha; Maria Lucia Fleiuss de Farias
Journal:  J Clin Endocrinol Metab       Date:  2013-03-12       Impact factor: 5.958

8.  Bone mineral density in acromegaly: the effect of gender, disease activity and gonadal status.

Authors:  Alfredo Scillitani; Claudia Battista; Iacopo Chiodini; Vincenzo Carnevale; Saverio Fusilli; Enrica Ciccarelli; Massimo Terzolo; Giuseppe Oppizzi; Maura Arosio; Maurizio Gasperi; Giorgio Arnaldi; Annamaria Colao; Roberto Baldelli; Maria Rosaria Ghiggi; Daniela Gaia; Carolina Di Somma; Vincenzo Trischitta; Antonio Liuzzi
Journal:  Clin Endocrinol (Oxf)       Date:  2003-06       Impact factor: 3.478

9.  Determinants of clinical outcome and survival in acromegaly.

Authors:  C Rajasoorya; I M Holdaway; P Wrightson; D J Scott; H K Ibbertson
Journal:  Clin Endocrinol (Oxf)       Date:  1994-07       Impact factor: 3.478

Review 10.  IGF-1 and bone: New discoveries from mouse models.

Authors:  Shoshana Yakar; Hayden-William Courtland; David Clemmons
Journal:  J Bone Miner Res       Date:  2010-12       Impact factor: 6.741

View more
  4 in total

1.  Elevated serum IGF-1 level enhances retinal and choroidal thickness in untreated acromegaly patients.

Authors:  Xia Zhang; Jin Ma; Yuhan Wang; Lüe Li; Lu Gao; Xiaopeng Guo; Bing Xing; Yong Zhong
Journal:  Endocrine       Date:  2018-01-10       Impact factor: 3.633

Review 2.  Determinants of skeletal fragility in acromegaly: a systematic review and meta-analysis.

Authors:  Cláudia Ribeiro de Moura; Sara Campos Lopes; Ana Margarida Monteiro
Journal:  Pituitary       Date:  2022-07-22       Impact factor: 3.599

3.  Alternative splicing of leptin receptor overlapping transcript in osteosarcoma.

Authors:  Emel Rothzerg; Xuan D Ho; Jiake Xu; David Wood; Aare Märtson; Katre Maasalu; Sulev Kõks
Journal:  Exp Biol Med (Maywood)       Date:  2020-08-12

4.  Preoperative and Postoperative Bone Mineral Density Change and Risk Factor Analysis in Patients with a GH-Secreting Pituitary Adenoma.

Authors:  Li'nan Qin; Xiaopeng Guo; Lu Gao; Zihao Wang; Chenzhe Feng; Kan Deng; Wei Lian; Bing Xing
Journal:  Int J Endocrinol       Date:  2019-11-03       Impact factor: 3.257

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.